These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Sustained limitation of myocardial reperfusion injury by a monoclonal antibody that alters leukocyte function. Simpson PJ; Todd RF; Mickelson JK; Fantone JC; Gallagher KP; Lee KA; Tamura Y; Cronin M; Lucchesi BR Circulation; 1990 Jan; 81(1):226-37. PubMed ID: 2153476 [TBL] [Abstract][Full Text] [Related]
3. Effect of anti-CD18 antibody on myocardial neutrophil accumulation and infarct size after ischemia and reperfusion in dogs. Tanaka M; Brooks SE; Richard VJ; FitzHarris GP; Stoler RC; Jennings RB; Arfors KE; Reimer KA Circulation; 1993 Feb; 87(2):526-35. PubMed ID: 8093866 [TBL] [Abstract][Full Text] [Related]
5. A chimeric IgG4 monoclonal antibody directed against CD18 reduces infarct size in a primate model of myocardial ischemia and reperfusion. Aversano T; Zhou W; Nedelman M; Nakada M; Weisman H J Am Coll Cardiol; 1995 Mar; 25(3):781-8. PubMed ID: 7860929 [TBL] [Abstract][Full Text] [Related]
7. Identification of a time window for therapy to reduce experimental canine myocardial injury: suppression of neutrophil activation during 72 hours of reperfusion. Simpson PJ; Fantone JC; Mickelson JK; Gallagher KP; Lucchesi BR Circ Res; 1988 Dec; 63(6):1070-9. PubMed ID: 2461814 [TBL] [Abstract][Full Text] [Related]
8. An anti-CD18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48-hour reperfusion. Arai M; Lefer DJ; So T; DiPaula A; Aversano T; Becker LC J Am Coll Cardiol; 1996 Apr; 27(5):1278-85. PubMed ID: 8609356 [TBL] [Abstract][Full Text] [Related]
9. Factors modifying protective effect of anti-CD18 antibodies on myocardial reperfusion injury in dogs. Perez RG; Arai M; Richardson C; DiPaula A; Siu C; Matsumoto N; Hildreth JE; Mariscalco MM; Smith CW; Becker LC Am J Physiol; 1996 Jan; 270(1 Pt 2):H53-64. PubMed ID: 8769734 [TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody to ICAM-1 preserves postischemic blood flow and reduces infarct size after ischemia-reperfusion in rabbit. Zhao ZQ; Lefer DJ; Sato H; Hart KK; Jefforda PR; Vinten-Johansen J J Leukoc Biol; 1997 Sep; 62(3):292-300. PubMed ID: 9307067 [TBL] [Abstract][Full Text] [Related]
12. Protection of ischemic/reperfused canine myocardium by CL18/6, a monoclonal antibody to adhesion molecule ICAM-1. Hartman JC; Anderson DC; Wiltse AL; Lane CL; Rosenbloom CL; Manning AM; Humphrey WR; Wall TM; Shebuski RJ Cardiovasc Res; 1995 Jul; 30(1):47-54. PubMed ID: 7553723 [TBL] [Abstract][Full Text] [Related]
13. Dynamic progression of contractile and endothelial dysfunction and infarct extension in the late phase of reperfusion. Zhao ZQ; Nakamura M; Wang NP; Velez DA; Hewan-Lowe KO; Guyton RA; Vinten-Johansen J J Surg Res; 2000 Dec; 94(2):133-44. PubMed ID: 11104653 [TBL] [Abstract][Full Text] [Related]
14. The role of serotonin (5HT2) receptor blockade in myocardial reperfusion injury: effects of LY53857 in a canine model of myocardial infarction. Simpson PJ; Schelm JA; Jakubowski JA; Smallwood JK J Pharmacol Exp Ther; 1991 Sep; 258(3):979-85. PubMed ID: 1653847 [TBL] [Abstract][Full Text] [Related]
15. Effects of a monoclonal antibody directed against P-selectin after myocardial ischemia and reperfusion. Lefer DJ; Flynn DM; Buda AJ Am J Physiol; 1996 Jan; 270(1 Pt 2):H88-98. PubMed ID: 8769738 [TBL] [Abstract][Full Text] [Related]
16. Effect of duration of ischaemia on reduction of myocardial infarct size by inhibition of neutrophil accumulation using an anti-CD18 monoclonal antibody. Williams FM; Kus M; Tanda K; Williams TJ Br J Pharmacol; 1994 Apr; 111(4):1123-8. PubMed ID: 7913371 [TBL] [Abstract][Full Text] [Related]
17. Adenosine attenuates reperfusion-induced apoptotic cell death by modulating expression of Bcl-2 and Bax proteins. Zhao ZQ; Budde JM; Morris C; Wang NP; Velez DA; Muraki S; Guyton RA; Vinten-Johansen J J Mol Cell Cardiol; 2001 Jan; 33(1):57-68. PubMed ID: 11133223 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic defibrination with ancrod does not protect canine myocardium from reperfusion injury. Simpson PJ; Schelm JA; Smith GF J Pharmacol Exp Ther; 1991 Feb; 256(2):780-6. PubMed ID: 1704437 [TBL] [Abstract][Full Text] [Related]
19. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Arslan F; Smeets MB; O'Neill LA; Keogh B; McGuirk P; Timmers L; Tersteeg C; Hoefer IE; Doevendans PA; Pasterkamp G; de Kleijn DP Circulation; 2010 Jan; 121(1):80-90. PubMed ID: 20026776 [TBL] [Abstract][Full Text] [Related]
20. Reduction of myocardial ischemia-reperfusion injury by KT-362, a new intracellular calcium antagonist in anesthetized dogs. Pelc LR; Farber NE; Warltier DC; Gross GJ J Cardiovasc Pharmacol; 1989 Apr; 13(4):586-93. PubMed ID: 2470996 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]